CION Ameerpet
Pancreatic Cancer · Types, Location & Resectability · Reviewed by CION Oncologists
Acinar cell carcinoma of the pancreas — a rare type, and a different one
Acinar cell carcinoma is an uncommon pancreatic cancer that grows from the enzyme-making cells, not from the duct lining. If this is the type on your pathology report, most of what you have been reading about pancreatic cancer was written about a different tumour — this page explains what actually changes.
- Pathology settles the type, not the scan — acinar and ductal tumours can look similar on imaging.
- The general figures do not describe it — almost everything published describes ductal adenocarcinoma.
- CA 19-9 is often unremarkable here — a normal marker proves nothing either way in this tumour.
- Genetic testing changes the plan more often — DNA-repair findings can steer the class of treatment chosen.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What Acinar Cell Carcinoma Actually Is
The pancreas has two working populations of cells. The acinar cells make the digestive enzymes that break down food. The duct cells form the plumbing that carries those enzymes into the bowel. Acinar cell carcinoma grows from the enzyme-making cells. Pancreatic ductal adenocarcinoma, the tumour almost everybody means when they say pancreatic cancer, grows from the duct lining. Same organ, different cell of origin, and in several practical ways a different disease.
That distinction matters more than it sounds. If your report names acinar cell carcinoma, the articles you have been reading in the last few days were written about ductal adenocarcinoma, because that is the overwhelming majority of pancreatic cancers. Their timelines, their treatment sequences and above all their outlook figures describe that tumour. Carrying them across to acinar pancreatic cancer is not cautious — it is simply the wrong reference book.
Acinar cell carcinoma is rare enough that many doctors outside specialist cancer practice will see very few in a working lifetime. It can arise anywhere in the gland. It is often larger and more clearly defined on a scan than a ductal tumour would be at the same point, and it tends to push against neighbouring structures rather than infiltrate them invisibly. Because it frequently sits away from the bile duct, it often does not cause early jaundice, so the one warning sign most people have heard of may never appear here.
None of that makes it a mild diagnosis. It is a cancer and it is treated as one. But the type on the report decides which body of evidence applies to you, which is why getting that type confirmed properly is the first thing worth doing.
Did you know? NCCN guidance recommends that everyone diagnosed with an exocrine pancreatic cancer — acinar cell carcinoma included — is offered genetic counselling and germline testing, whatever their age and whatever their family history. That recommendation is not a formality on this tumour. Acinar cell carcinoma is reported to carry inherited and tumour changes in the DNA-damage-repair pathway, including BRCA and related genes, more often than ductal adenocarcinoma does. A positive result can influence which class of chemotherapy is chosen, whether maintenance treatment is on the table, and what screening your brothers, sisters and children should be offered. Genetic counselling and the test itself are done in-house at CION.
Where it behaves differently
What Sets This Rare Pancreatic Cancer Type Apart
These are the features that most often surprise people who have been reading general pancreatic cancer material.
Cell of origin
The enzyme cells, not the ducts
It arises from the acinar cells that produce digestive enzymes. The pathologist confirms this with stains for those enzyme markers, and that is what separates it from a ductal or a neuroendocrine tumour.
On the scan
Often large, and better defined
These tumours are commonly bulkier and more clearly outlined than ductal cancers, sometimes with a capsule-like edge. Size alone here says less about how advanced things are than it would in a ductal tumour.
Blood markers
CA 19-9 is often unremarkable
A normal CA 19-9 does not rule this tumour out, and a raised one is not the tracking tool it can be in ductal disease. Do not read reassurance into that number on this diagnosis.
Uncommon pattern
Symptoms away from the abdomen
A small number of these tumours release large amounts of enzyme into the blood, producing tender fatty lumps under the skin, joint pain and sometimes bone pain. It is called lipase hypersecretion syndrome, and it is occasionally what leads to the diagnosis.
Mixed tumours
Acinar and neuroendocrine together
The WHO classification of digestive system tumours recognises mixed acinar-neuroendocrine carcinoma as its own entity. Where both patterns are present the report should say so, because it changes the discussion.
Underlying biology
DNA-repair changes turn up more often
Faults in the DNA-damage-repair machinery are found more frequently than in ductal adenocarcinoma. That is a genuinely useful finding, because it points towards particular classes of systemic treatment.
Side by side
Acinar, Ductal and Neuroendocrine Compared
Three pancreatic tumours, three different reference points. This is the comparison worth having in front of you when you read your own report.
| What is being compared | Acinar cell carcinoma | Ductal adenocarcinoma | Neuroendocrine tumour |
|---|---|---|---|
| Cell it grows from | The acinar cells that make digestive enzymes | The lining of the pancreatic ducts | The hormone-producing islet cells |
| How often it is seen | Rare | The large majority of pancreatic cancers | Uncommon, and a genuinely separate disease |
| Usual look on a scan | Often a bulky, reasonably well-outlined mass | Usually ill-defined, narrowing the duct behind it | Often well-defined and brightly enhancing |
| Early jaundice | Less typical, as it often sits away from the bile duct | Common where the tumour is in the head | Uncommon unless it sits at the head |
| CA 19-9 | Frequently unremarkable, and not a reliable guide here | Often raised, and useful to track once it is | Not the marker used for this tumour |
| How the report grades it | On how the cells look and how briskly they divide | On how well the tumour still forms glands | On the proportion of dividing cells |
| Route to cure | Complete surgical removal where the tumour can be taken out | Complete removal, followed by chemotherapy | Surgery, with a wider set of options in slow-growing disease |
| Systemic treatment | Combination chemotherapy, with the DNA-repair result influencing the class chosen | Combination chemotherapy, with PARP-inhibitor-class maintenance where BRCA-mutated | Somatostatin-analogue-class and other targeted options |
If the type named on your report is not the type you have spent the week reading about, bring the report in and have it read properly. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
The Type on the Report Decides Which Evidence Applies
Acinar cell carcinoma is not the tumour most pancreatic cancer articles are describing.
What actually happens
From a Suspected Acinar Tumour to an Actual Plan
-
A pancreatic-protocol contrast CT
Not an ordinary abdominal scan. The contrast timing is set so the tumour’s relationship to the arteries and veins behind the pancreas can be described precisely, which is what decides whether an operation is on the table.
Ordered and reported in-house at CION -
Tissue, and a pathologist who has seen this before
An endoscopic ultrasound with a fine-needle sample provides the tissue. Enzyme-marker stains then separate acinar cell carcinoma from ductal and neuroendocrine tumours. On a rare tumour, a specialist review of the slides is worth asking for.
Coordinated with specialist endoscopy partners -
Genetic counselling and germline testing
Offered because guidance says it should be, and because on this tumour a DNA-repair finding genuinely changes the conversation — about your own treatment, and about testing for close relatives.
In-house at CION -
Completing the staging picture
MRI clarifies indeterminate spots in the liver. Functional imaging and, in selected cases, a staging laparoscopy are used where the answer would change the plan, not as a routine.
MRI in-house; PET-CT and staging laparoscopy coordinated -
The case is discussed as a team
Imaging, pathology, nutrition and general fitness are reviewed together, so the plan reflects what medical oncology, radiation oncology and the surgical partners each think is achievable rather than one opinion.
HPB tumour board at CION -
The plan is written down, with its decision points
Surgery where the tumour can be removed; combination chemotherapy before or after it, or as the main treatment where it cannot. Pancreatic cancer treatment in Hyderabad sets out the options in full.
Systemic therapy and radiation in-house at CION; surgery coordinated -
Nutrition, enzymes and pain from the first week
A tumour of the enzyme-making cells can leave you short of the enzymes themselves. Pancreatic enzyme replacement, dietetic input and proper pain control start alongside treatment, not after it.
In-house at CION
Plainly stated
What CION Delivers, and What Is Coordinated
Your first consultation is free and lasts 45 minutes. It is a genuine review of your scan and pathology reports by a medical oncologist, not a booking appointment, and on a rare tumour that time is mostly spent making sure the diagnosis itself is solid before anything is planned around it.
Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: medical oncology — chemotherapy before surgery, after surgery and for advanced disease; PARP-inhibitor-class maintenance where an inherited BRCA change is found; and immune checkpoint inhibitor therapy where the tumour is mismatch-repair deficient. Also radiation, chemoradiation and SBRT; the ordering and reporting of pancreatic-protocol CT, MRI and MRCP, CA 19-9 and routine bloods; genetic counselling and germline testing; nutrition and pancreatic enzyme replacement; pain relief, psycho-oncology and supportive care; and survivorship follow-up.
Coordinated with specialist HPB, gastroenterology and endoscopy partner centres, and may be billed there: all pancreatic surgery, including the Whipple procedure and distal or total pancreatectomy; endoscopic ultrasound with biopsy; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block for pain; PET-CT and DOTATATE PET; and peptide receptor radionuclide therapy. We arrange these, we sit in on the decisions, and we tell you in advance where each one happens and who invoices you. We do not describe them as our own theatre or endoscopy lists, because they are not.
If you want the wider picture rather than this one tumour type, the complete guide to pancreatic cancer covers symptoms, diagnosis, treatment and cost in one place.
Bring the pathology report and the scan report to the first appointment. On a rare tumour those two documents settle more than anything you will find online tonight. Book a free consultation or call 1800 202 8726.
Take the next step
Get the Diagnosis Confirmed Properly First
We walk this journey with you, with the time to explain what your own reports actually say.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Acinar cell carcinoma - your questions answered
What is acinar cell carcinoma of the pancreas?
It is an uncommon pancreatic cancer that grows from the acinar cells, the cells that make digestive enzymes. The far more common pancreatic cancer, ductal adenocarcinoma, grows from the lining of the pancreatic ducts instead. Because the cell of origin is different, acinar cell carcinoma looks different under the microscope, is confirmed with different stains, often looks different on a scan, and does not always behave the same way. It is confirmed on pathology rather than on imaging, so a scan alone cannot tell you that this is what you have. The World Health Organization classification of digestive system tumours lists it as an entity in its own right, separate from ductal adenocarcinoma and from pancreatic neuroendocrine tumours.
How is acinar cell carcinoma different from ductal adenocarcinoma?
The practical differences start with the report. Acinar tumours are often bulkier and more clearly outlined on a scan, and because they frequently sit away from the bile duct they less often cause the early painless jaundice that brings ductal head tumours to attention. CA 19-9 is frequently unremarkable, so it is not the tracking marker it can be in ductal disease. Faults in the DNA-damage-repair pathway are found more often, which is one reason genetic testing carries more weight here. The route to cure is the same in principle, complete surgical removal, but the systemic treatment discussion is shaped by that biology rather than copied across from ductal practice.
Why is my CA 19-9 normal if I have pancreatic cancer?
This is one of the most common questions on this diagnosis, and it does not mean a mistake has been made. CA 19-9 is a blood marker that is often, though not always, raised in ductal adenocarcinoma. In acinar cell carcinoma it is frequently unremarkable. A normal result here therefore proves nothing in either direction: it does not rule the tumour out, and it does not indicate that the disease is limited. It also means the marker is usually not the right tool for following your response to treatment, so your team will more likely track the disease on imaging and on how you are in yourself instead.
What causes the tender lumps and joint pains some people get?
In a small number of these tumours, large amounts of pancreatic enzyme are released into the bloodstream. That can produce tender fatty lumps in the skin, particularly on the legs, along with joint pain, sometimes bone pain, and a rise in one type of white blood cell. It is known as lipase hypersecretion syndrome. It is uncommon, but it is well described, and it is occasionally what leads to the tumour being found in the first place. If you have these symptoms alongside a pancreatic mass, say so clearly to your team, because the two are connected and the symptoms usually settle as the tumour is treated.
Does genetic testing really matter for a rare pancreatic cancer type?
Yes, and more than most people expect. NCCN guidance already recommends germline testing for everyone with an exocrine pancreatic cancer, whatever their age or family history. On acinar cell carcinoma it matters more, because changes in the DNA-damage-repair pathway, including BRCA and related genes, are reported more often than in ductal adenocarcinoma. A finding can influence which class of chemotherapy is chosen and whether maintenance treatment is discussed at all. It also matters beyond your own treatment: an inherited change has implications for your brothers, sisters and children, who can then be offered counselling and testing themselves. Genetic counselling and testing are provided in-house at CION.
What does CION do for acinar cell carcinoma, and what happens at the first visit?
The first consultation is free and lasts 45 minutes with a medical oncologist. Bring the pathology report, the scan report and the discs if you have them. We check that the type has been confirmed properly, ask for a specialist slide review where that is worth doing, and set out what the reports do and do not settle. Chemotherapy, radiation, chemoradiation and SBRT, imaging and blood test ordering and reporting, genetic counselling, nutrition and enzyme support, pain relief, psycho-oncology and survivorship care are delivered by CION across 35+ centres. All pancreatic surgery, endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy and PET-CT are coordinated with specialist partner centres and may be billed there. We tell you which is which before anything is booked.
Medical disclaimer: This page explains what acinar cell carcinoma of the pancreas is and how it is distinguished from ductal adenocarcinoma and pancreatic neuroendocrine tumours. It is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma and to the WHO classification of digestive system tumours. It is general information and deliberately states no survival figure, because no published figure describes an individual; your own diagnosis and plan should be confirmed with your treating team. Chemotherapy, radiation, chemoradiation and SBRT, imaging and CA 19-9 ordering and reporting, genetic counselling and germline testing, nutrition and pancreatic enzyme support, pain relief, psycho-oncology and survivorship care are delivered by CION; all pancreatic surgery, endoscopic ultrasound and biopsy, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, and peptide receptor radionuclide therapy are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there.